Challenges in Pediatric Drug Approvals

Biomedical research has led to incredible advancements and saved numerous lives. However, many promising drugs are currently stuck in federal reviews, and it’s the children with rare diseases who are suffering the consequences.

As a biological scientist, I’ve dedicated my career to understanding healthy cell functions and translating that knowledge into therapeutic enzymes. My work spans treatment protocols, safety through multi-level trials, and setting evidence standards, all aimed at ensuring that new treatments reach patients effectively.

One might wonder—do bureaucracies really hinder progress this much? Or do treatments for rare pediatric conditions encounter significantly higher barriers within current systems?

While standards and processes are essential, the urgency cannot be overlooked. Children facing rare diseases don’t operate on a regulatory timeline. Each month brings lost abilities—whether it’s speech, mobility, independence, or even the capacity to breathe unaided.

Among the 6,800 recognized rare diseases, around 70% manifest during childhood. Take Duchenne muscular dystrophy, Gaucher disease, or cystic fibrosis; these are well-known examples.

Creating treatments for these children is not just hard; it’s often prohibitively expensive and long-winded, even under optimal circumstances. Consider treatments like Ultragenyx UX111 for Sanfilippo syndrome or Erevidis from Sarepta for Duchenne. The challenges can stretch out for years, ultimately delaying crucial access to children in desperate need.

This situation makes it increasingly difficult to justify regulatory delays that could have been avoided.

More often than not, applications don’t fail due to the science behind them but stall because of issues like manufacturing or procedural concerns. These problems are often fixable and don’t necessarily correlate with treatment efficacy. It raises doubts about whether the expedited approval pathways of the FDA are fulfilling their intended purpose of speeding up access to critical treatments while still gathering necessary data.

As a scientist, I found the FDA’s recent decision to reject the application for a promising Hunter syndrome treatment particularly concerning, especially after positive trial results led to yet another hold on its development.

This brings to light an uncomfortable question: does the review process itself warrant a review?

The challenges surrounding UX111 serve as another illustration. This treatment faced extensive trials, but manufacturing holds only prolonged the approval process.

Elevidis provides another painful example. Two non-ambulatory patients, including one with existing health issues, tragically lost their lives during a treatment protocol involving over 1,200 Duchenne patients. Following these incidents, FDA halted the treatment, leaving families feeling overwhelmed and panicked.

Children have been in limbo for too long, waiting for transformative treatments.

Yes, we’re seeing medical advances, but the regulatory challenges seem to be multiplying. A decade can slip by before many treatments reach the market, and in the context of rare childhood diseases, that delay has a harsh moniker: “time children don’t have.”

In some scenarios, this translates to children losing their entire lives.

It’s angering to think that while manufacturing processes can be refined and documentation adjusted, once lost neurons and muscle fibers cannot be regained.

It’s crucial for FDA leaders to collaborate with Congress and the White House to foster a more agile approval process—one that can juggle multiple requirements efficiently rather than extending timelines unnecessarily. If the regulatory framework had been smoothed out, treatments for Sanfilippo could have stuck to their original 2025 schedule, while Duchenne patients might not have been deprived of the only viable gene therapy option.

This discussion doesn’t imply conceding safety and efficacy standards.

Ultragenyx indicated that manufacturing refinements could be pursued without affecting product quality. Sarepta addressed FDA’s concerns about Elevidis by allowing outpatient treatment to proceed, albeit with a black box warning. Conversely, in the case of RGX-121 for Hunter syndrome, the FDA rejected a long-established biomarker (cerebrospinal fluid) previously utilized in clinical trials.

These regulatory decisions are not aiding children facing rare diseases; rather, they hinder timely, science-based approvals.

The ramifications extend beyond just current patients; the regulatory efficiency also impacts future investments in rare disease therapies. Developing orphan drugs requires significant initial investment, lengthy timelines, and often yields limited economic returns. Frequently, these programs resemble more of a charitable endeavor than a booming pharmacoeconomic success.

When developers encounter continual slowdowns across a range of conditions, technologies, and sponsors—often unlinked to the core safety or efficacy of their products—the message to the market is stark: “avoid risks.”

This is how innovation becomes stifled.

At some point, the pattern observed with the FDA becomes hard to overlook. Is it simply bureaucratic inertia at play? Or are rare pediatric treatments facing uniquely elevated challenges within the current system?

These questions—scientific and ethical in nature—deserve transparent discussions.

Expedited approvals don’t equate to compromising standards. It’s about applying these standards judiciously—permitting earlier access while ensuring that evidence continues to build. Recognizing that a “wait and see” approach is not neutral; it’s a decision that guarantees disease progression in children who can’t afford delays.

Good science and compassion don’t stand at odds. We can be both urgent and rigorous.

The authority lies with the FDA. The science is evolving. But the children simply can’t wait.

Accelerated approvals don’t mean cutting corners. Every available tool must be used to save the time that families desperately need.